Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver.
For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market. This report examines in detail the drugs, devices, therapeutics and markets that are set to drive the market for subcutaneous self-administration into the next decade.
Subcutaneous Self-Administration Markets to 2024 - What You Will Learn
- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments - Provides market data and forecasts to 2024 - Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations - Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization - Evaluates the impact of economic, technology, and regulatory factors